Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014) (RESTORE-IMI 2)
. Accessed February 24, 2020; ClinicalTrials.gov Identifier: NCT02493764